Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Erlotinib Stories

2013-10-21 10:09:54

The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung...

2013-10-16 04:21:50

SAN DIEGO, Calif., Oct. 16, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) "We are pleased to launch a...

2013-09-30 04:22:27

ANTWERP, Belgium, September 30, 2013 /PRNewswire/ -- Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), today announces that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level. The new kits enable PCR amplification of genes known to be frequently mutated in...

2013-07-26 11:16:52

Testing dropped once funding from pharmaceutical industry was discontinued Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation...

2013-07-24 08:29:48

PITTSBURGH, July 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This product is the generic version of TARCEVA(®), and is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or...

2013-06-27 23:20:05

BioPlus selected as a specialty pharmacy for the new Tarceva network; now authorized to dispense this oncology medication. Altamonte Springs, FL (PRWEB) June 27, 2013 The medication Tarceva® (erlotinib) from Genentech and Astellas Pharma US, Inc. will no longer be distributed through retail pharmacies, effective July 1, 2013. Tarceva will be supplied through BioPlus Specialty Pharmacy (BioPlus) and other select specialty pharmacies. Tarceva is a once daily oral non-chemotherapy...

2013-05-20 12:26:59

Study Results Show Promise and Indicate Further Investigation is Warranted SCHAUMBURG, Ill., May 20, 2013 /PRNewswire-USNewswire/ -- The use of vitamin C to treat cancer patients first became popular in the 1970s as a result of the work of Nobel Laureate Linus Pauling. However, studies conducted with orally dosed supplements did not demonstrate any clinical benefit in cancer patients, most likely due to the finding that the levels of orally-administered vitamin C delivered to a...

2013-05-14 08:28:56

--Results Published in Journal of Clinical Oncology Show for the First Time that Adding Entinostat to Antiestrogen Therapy May Be an Effective Approach to Targeting Resistance Pathways in Breast Cancer-- WALTHAM, Mass., May 14, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in the Journal of...

2013-04-08 12:28:40

NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...

2013-04-04 08:28:31

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). MM-121 is being evaluated in two additional NSCLC cohorts as well as Phase 2 studies for the treatment of...